HomeCompareBIOR vs NOBL

BIOR vs NOBL: Dividend Comparison 2026

BIOR yields 909.09% · NOBL yields 2.17%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BIOR wins by $8252648.19M in total portfolio value
10 years
BIOR
BIOR
● Live price
909.09%
Share price
$0.22
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8252648.21M
Annual income
$6,784,560,004,057.53
Full BIOR calculator →
NOBL
NOBL
● Live price
2.17%
Share price
$104.67
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.9K
Annual income
$249.78
Full NOBL calculator →

Portfolio growth — BIOR vs NOBL

📍 BIOR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBIORNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BIOR + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BIOR pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BIOR
Annual income on $10K today (after 15% tax)
$77,272.73/yr
After 10yr DRIP, annual income (after tax)
$5,766,876,003,448.90/yr
NOBL
Annual income on $10K today (after 15% tax)
$184.52/yr
After 10yr DRIP, annual income (after tax)
$212.31/yr
At 15% tax rate, BIOR beats the other by $5,766,876,003,236.59/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BIOR + NOBL for your $10,000?

BIOR: 50%NOBL: 50%
100% NOBL50/50100% BIOR
Portfolio after 10yr
$4126324.12M
Annual income
$3,392,280,002,153.66/yr
Blended yield
82.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BIOR right now

BIOR
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-109.2
Piotroski
4/9
NOBL
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BIOR buys
0
NOBL buys
0
No recent congressional trades found for BIOR or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBIORNOBL
Forward yield909.09%2.17%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$8252648.21M$22.9K
Annual income after 10y$6,784,560,004,057.53$249.78
Total dividends collected$8138900.96M$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: BIOR vs NOBL ($10,000, DRIP)

YearBIOR PortfolioBIOR Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$101,609$90,909.09$10,917$217.08+$90.7KBIOR
2$972,011$863,288.79$11,903$221.48+$960.1KBIOR
3$8,758,157$7,718,105.75$12,962$225.68+$8.75MBIOR
4$74,364,546$64,993,317.91$14,099$229.68+$74.35MBIOR
5$595,318,755$515,748,691.06$15,319$233.49+$595.30MBIOR
6$4,495,664,203$3,858,673,134.79$16,628$237.10+$4495.65MBIOR
7$32,043,550,537$27,233,189,840.42$18,033$240.53+$32043.53MBIOR
8$215,696,715,677$181,410,116,602.38$19,539$243.78+$215696.70MBIOR
9$1,372,045,052,584$1,141,249,566,809.58$21,154$246.86+$1372045.03MBIOR
10$8,252,648,210,323$6,784,560,004,057.53$22,884$249.78+$8252648.19MBIOR

BIOR vs NOBL: Complete Analysis 2026

BIORStock

Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

Full BIOR Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this BIOR vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BIOR vs SCHDBIOR vs JEPIBIOR vs OBIOR vs KOBIOR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.